Stratos Wealth Partners LTD. Trims Stock Position in Zevra Therapeutics, Inc. $ZVRA

Stratos Wealth Partners LTD. lessened its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 29.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 220,000 shares of the company’s stock after selling 90,000 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Zevra Therapeutics were worth $1,938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after purchasing an additional 8,020 shares during the last quarter. Strs Ohio purchased a new position in shares of Zevra Therapeutics during the first quarter worth $125,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares during the last quarter. EntryPoint Capital LLC raised its holdings in shares of Zevra Therapeutics by 53.8% during the first quarter. EntryPoint Capital LLC now owns 40,675 shares of the company’s stock worth $305,000 after purchasing an additional 14,225 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Zevra Therapeutics by 9.6% in the first quarter. Rhumbline Advisers now owns 74,585 shares of the company’s stock valued at $559,000 after buying an additional 6,532 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analyst Weigh In

ZVRA has been the subject of a number of recent analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Wall Street Zen cut shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. Cantor Fitzgerald lifted their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. Zacks Research cut shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Insider Transactions at Zevra Therapeutics

In other news, Director John B. Bode bought 5,000 shares of the firm’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $412,200. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the completion of the transaction, the chief executive officer owned 222,016 shares in the company, valued at $2,402,213.12. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $11.15 on Tuesday. Zevra Therapeutics, Inc. has a 52-week low of $6.19 and a 52-week high of $13.16. The firm has a market capitalization of $625.85 million, a price-to-earnings ratio of -53.10 and a beta of 1.49. The company has a fifty day simple moving average of $9.33 and a 200-day simple moving average of $9.24. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). The business had revenue of $25.88 million for the quarter, compared to analyst estimates of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. On average, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.